Oct 21, 2022 8:00 am EDT Nighthawk Biosciences’ Scorpion Subsidiary Announces Grand Opening of its San Antonio Facility
Aug 23, 2022 7:30 am EDT NightHawk Biosciences Announces Buildout of Advanced Biosafety Level 2 (BSL-2) Laboratory
Jun 13, 2022 8:00 am EDT NightHawk Biosciences Appoints Stephan Kutzer, Ph.D. as Interim Chief Executive Officer of Scorpion Biological Services
May 10, 2022 8:00 am EDT NightHawk Biosciences to Present at the 4th Annual Treg Directed Therapies Summit on PTX-35
May 03, 2022 7:00 am EDT Heat Biologics Completes Name Change to NightHawk Biosciences; Trading to Commence Under “NHWK” Effective at the Market Open Today
Apr 27, 2022 8:00 am EDT Heat Biologics (NightHawk Biosciences) Announces that its Elusys Therapeutics Subsidiary has Executed a Contract to Deliver ANTHIM® to the Canadian Government